Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Lonza will expand its viral-based therapeutics business with the construction of a clean room at its Houston facility. To open early next year, the clean room will house disposable bioreactors of up to 2,000 L that support late-stage viral vaccine and gene therapy projects. Lonza entered viral manufacturing in August 2010 through the acquisition of Houston-based Vivante GMP Solutions. The Swiss firm says viral vaccines are cheaper to make than traditional egg-based vaccines.
This article has been sent to the following recipient: